| pubmed-article:19444142 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0028754 | lld:lifeskim |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0005823 | lld:lifeskim |
| pubmed-article:19444142 | lifeskim:mentions | umls-concept:C0441994 | lld:lifeskim |
| pubmed-article:19444142 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:19444142 | pubmed:dateCreated | 2009-6-22 | lld:pubmed |
| pubmed-article:19444142 | pubmed:abstractText | To compare the long-term efficacy, safety and tolerability of the direct renin inhibitor aliskiren against the diuretic hydrochlorothiazide (HCTZ) in obese patients with hypertension. | lld:pubmed |
| pubmed-article:19444142 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19444142 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19444142 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19444142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19444142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19444142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19444142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19444142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19444142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19444142 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19444142 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:19444142 | pubmed:issn | 1473-5598 | lld:pubmed |
| pubmed-article:19444142 | pubmed:author | pubmed-author:SchmiederRola... | lld:pubmed |
| pubmed-article:19444142 | pubmed:author | pubmed-author:PhilippThomas... | lld:pubmed |
| pubmed-article:19444142 | pubmed:author | pubmed-author:KeefeDeborah... | lld:pubmed |
| pubmed-article:19444142 | pubmed:author | pubmed-author:BushChristoph... | lld:pubmed |
| pubmed-article:19444142 | pubmed:author | pubmed-author:GorostidiManu... | lld:pubmed |
| pubmed-article:19444142 | pubmed:author | pubmed-author:GuerediagaJav... | lld:pubmed |
| pubmed-article:19444142 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19444142 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:19444142 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19444142 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19444142 | pubmed:pagination | 1493-501 | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:meshHeading | pubmed-meshheading:19444142... | lld:pubmed |
| pubmed-article:19444142 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19444142 | pubmed:articleTitle | Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. | lld:pubmed |
| pubmed-article:19444142 | pubmed:affiliation | Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany. Roland.Schmieder@rzmail.uni-erlangen.de | lld:pubmed |
| pubmed-article:19444142 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19444142 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19444142 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
